- Home
- TCBIO vs TNGX Comparison
TCBIO vs TNGX Comparison
Compare TCBIO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBIO
- TNGX
- Stock Information
- Founded
- TCBIO N/A
- TNGX 2014
- Country
- TCBIO United States
- TNGX United States
- Employees
- TCBIO 1818
- TNGX N/A
- Industry
- TCBIO Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TCBIO Finance
- TNGX Health Care
- Exchange
- TCBIO Nasdaq
- TNGX Nasdaq
- Market Cap
- TCBIO N/A
- TNGX 351.2M
- IPO Year
- TCBIO N/A
- TNGX N/A
- Fundamental
- Price
- TCBIO $21.09
- TNGX $5.87
- Analyst Decision
- TCBIO
- TNGX Strong Buy
- Analyst Count
- TCBIO 0
- TNGX 6
- Target Price
- TCBIO N/A
- TNGX $12.20
- AVG Volume (30 Days)
- TCBIO N/A
- TNGX 2.9M
- Earning Date
- TCBIO N/A
- TNGX 08-06-2025
- Dividend Yield
- TCBIO N/A
- TNGX N/A
- EPS Growth
- TCBIO N/A
- TNGX N/A
- EPS
- TCBIO N/A
- TNGX N/A
- Revenue
- TCBIO N/A
- TNGX $40,990,000.00
- Revenue This Year
- TCBIO N/A
- TNGX N/A
- Revenue Next Year
- TCBIO N/A
- TNGX N/A
- P/E Ratio
- TCBIO N/A
- TNGX N/A
- Revenue Growth
- TCBIO N/A
- TNGX 10.09
- 52 Week Low
- TCBIO N/A
- TNGX $1.03
- 52 Week High
- TCBIO N/A
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TCBIO 65.80
- TNGX 74.27
- Support Level
- TCBIO $20.79
- TNGX $5.34
- Resistance Level
- TCBIO $21.72
- TNGX $5.63
- Average True Range (ATR)
- TCBIO 0.30
- TNGX 0.50
- MACD
- TCBIO -0.00
- TNGX -0.04
- Stochastic Oscillator
- TCBIO 50.88
- TNGX 84.15
About TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.